Updated:
AEON Biopharma
AEON Biopharma develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions. It restricts activity to therapeutic uses and reviews...
AEON Biopharma
AEON Biopharma develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions. It restricts activity to therapeutic uses and reviews additional indications through a product assessment process that weighs clinical, regulatory, and commercial factors.
General information
Firm type
Asset Manager
Location
Region
North America
Country
United States
City
Irvine
Corporate office
Irvine, CA, United States
Sector focus
Frequently asked questions
What is AEON Biopharma's core therapeutic focus?
AEON Biopharma develops injectable botulinum toxin therapeutics for neurological conditions. Its lead candidate, ABP-450, targets chronic migraine and cervical dystonia. The company explicitly focuses on therapeutic neurology rather than aesthetic applications of botulinum toxin.
Is AEON Biopharma structured as a family office or a biotech operating company?
AEON Biopharma is a publicly traded clinical-stage biotech operating company, not a family office or investment vehicle. It trades on the NYSE American exchange under the ticker AEON. There is no disclosed connection to a single-family wealth source or multi-family office structure.
Who runs investment decisions at AEON Biopharma?
AEON Biopharma does not function as an investment firm and has no external allocator function. Capital allocation decisions are corporate decisions made by management and the board, focused on clinical trial funding. The firm does not manage a portfolio of outside investments or external manager relationships.
Does AEON Biopharma participate in fund commitments or direct investments?
No. AEON Biopharma is an operating company that deploys capital solely into its own clinical programs and corporate infrastructure. It does not make fund commitments, direct co-investments, or venture allocations as a principal.
What is AEON Biopharma's known posture on co-investments alongside external GPs?
As a development-stage biotech company, AEON Biopharma has no co-investment program alongside external general partners. The firm's capital structure is that of an equity-financed operating company, not an institutional allocator, and no co-investment activity has been disclosed in public filings.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: